What drove the CHM.AX stock spike after hours on 09 Jan 2026?

The after-hours spike was driven by heavy buying around clinical and liquidity signals. CHM.AX stock traded **18,910,051** shares and rose **50.00%** to **A$0.003**, reflecting short-term news interest and low market cap dynamics.

What are realistic price targets for CHM.AX stock?

Near-term upside target from Meyka AI is **A$0.010** (quarterly forecast), implying **233.33%** upside. A downside support level is **A$0.002** (year low), implying **-33.33%** from today. Targets depend on trial and funding events.

How does CHM.AX stock compare on fundamentals?

CHM.AX stock shows EPS **-0.02**, PE **-0.20**, PB **1.72**, and price/sales **0.90**. These metrics reflect a clinical-stage biotech with negative earnings and constrained liquidity, common in the sector.

When is the next CHM.AX earnings or announcement window?

Earnings or announcement timing lists an upcoming date of **2026-02-26** for company disclosures. Clinical readouts can occur outside formal earnings, and those drive CHM.AX stock volatility.

AU Stocks

CHM.AX up 50.00% to A$0.003 on 18.9M volume after hours 09 Jan 2026: catalyst read

ByDanny Kontos January 9, 2026January 9, 2026

CHM.AX stock jumped 50.00% to A$0.003 on heavy after-hours volume of 18,910,051 shares on 09 Jan 2026. The move came on thin market capitalisation of A$8,217,600 and follows trading that opened at A$0.002 and closed prior at A$0.002. Chimeric Therapeutics Limited (ASX: CHM.AX) is a clinical-stage biotech focused on CAR T and NK cell therapies. Investors pushed the price toward the A$0.009 year high as clinical and liquidity signals drove the high-volume spike.